197 related articles for article (PubMed ID: 27436632)
1. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Yaroslavtseva T; Pecoraro A; Woody G
Am J Drug Alcohol Abuse; 2016 Sep; 42(5):614-620. PubMed ID: 27436632
[TBL] [Abstract][Full Text] [Related]
2. [Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral naltrexone or naltrexone implant].
Krupitsky EM; Zvartau EE; Blokhina EA; Verbitskaya EV; Wahlgren VY; Tsoy-Podosenin MV; Bushara NM; Burakov AM; Masalov DV; Romanova TN; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Sulimov GY; Pecoraro A; Woody G
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(1. Vyp. 2):26-33. PubMed ID: 29658501
[TBL] [Abstract][Full Text] [Related]
3. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.
Carroll KM; Nich C; Frankforter TL; Yip SW; Kiluk BD; DeVito EE; Sofuoglu M
Drug Alcohol Depend; 2018 Nov; 192():264-270. PubMed ID: 30300800
[TBL] [Abstract][Full Text] [Related]
4. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
5. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
6. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
[TBL] [Abstract][Full Text] [Related]
8. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
[TBL] [Abstract][Full Text] [Related]
9. Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.
Strang J; Kelleher M; Mayet S; Day E; Hellier J; Byford S; Murphy C; McLennan B; Shearer J; Ryan E; Marsden J
Health Technol Assess; 2019 Jan; 23(3):1-72. PubMed ID: 30702059
[TBL] [Abstract][Full Text] [Related]
10. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
[TBL] [Abstract][Full Text] [Related]
11. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
12. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
13. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
14. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
Lobmaier PP; Kunøe N; Gossop M; Waal H
CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
[TBL] [Abstract][Full Text] [Related]
16. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
17. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
18. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Tsoy M; Wahlgren V; Burakov A; Masalov D; Romanova TN; Palatkin V; Tyurina A; Yaroslavtseva T; Sinha R; Kosten TR
Drug Alcohol Depend; 2013 Oct; 132(3):674-80. PubMed ID: 23683793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
